by John A. Jenkins | Feb 4, 2026 | FDA, FOIA, Litigation, Pharmaceuticals, Stock Market
FOIAengine: Media Requests Were Warnings, Months Before Bad News Hit In the early days of the Covid pandemic, there was big money on the line as pharmaceutical companies scrambled to produce vaccines. The world needed a miracle. The companies that could deliver it...
by Randy E. Miller | Jan 22, 2026 | FDA, FOIA, Law Firms
FOIAengine: A Tale of Two Law Firms When most people think about the Freedom of Information Act, they imagine journalists prying loose hidden facts or activists holding officials accountable. But FOIA is also a workhorse tool for lawyers. As two law firms’ 2025 FOIA...
by John A. Jenkins | Jan 14, 2026 | FDA, FOIA, News Media, Pharmaceuticals
FOIAengine: Warning Letters and Inspection Reports in the Spotlight Freedom of Information Act requests filed with the Food and Drug Administration by hedge funds last month revealed big financial players closely eyeing warning letters, enforcement documents, and...
by John A. Jenkins | Jan 8, 2026 | FDA, FOIA, News Media, Pharmaceuticals
FOIAengine: Growing Scrutiny of Drug Safety and Enforcement As GLP-1 weight-loss drugs surge in popularity, major news organizations are pressing the Food and Drug Administration for internal records that reveal what regulators knew about reports of dangers...
by John A. Jenkins | Dec 10, 2025 | FDA, FOIA, News Media, Pharmaceuticals
FOIAengine: The Investigative Outlet Gets Active at the FDA Capitol Forum may be one of the more under-the-radar journalistic enterprises in Washington, but recently it was easily the most active when it came to filing FOIA requests with the Food and Drug...
by Randy E. Miller | Oct 16, 2025 | FDA, FOIA
FOIAengine: FDA Weight Loss Drug FOIA Requests Grow Leading makers of GLP-1 (Glucagon-Like Peptide-1) weight loss drugs like Ozempic and Zepbound are facing off against domestic compounding pharmacies that import foreign ingredients and make cheaper, non-approved...
